Cerebral Angiography Market by Equipment Type (Fixed, Mobile), Operation Mode (Analog, Digital), Application, End User - Global Forecast 2026-2032
Description
The Cerebral Angiography Market was valued at USD 5.98 billion in 2025 and is projected to grow to USD 6.37 billion in 2026, with a CAGR of 6.67%, reaching USD 9.40 billion by 2032.
An authoritative introduction framing how technological advances and clinical practice evolution are reshaping cerebral angiography delivery and strategic decision making
Cerebral angiography continues to occupy a pivotal role at the intersection of neurovascular diagnosis and minimally invasive intervention. Advances in imaging hardware, software, and procedural technique have converged to reshape how clinicians visualize cerebrovascular anatomy, assess pathological flow dynamics, and guide high-precision interventions. As the clinical community moves toward tighter integration of real-time imaging, contrast optimization, and dose-minimizing workflows, providers and device stakeholders face new imperatives around interoperability, service continuity, and evidence generation to demonstrate clinical and economic value.
This introduction frames the subsequent analysis by outlining core technological trends, evolving clinical pathways, and systemic pressures that influence procurement and adoption. It emphasizes the growing importance of digital transformation, hybrid procedure suites, and the alignment of clinical protocols with regulatory expectations. By situating cerebral angiography within broader shifts in imaging and vascular care, this section prepares readers to interpret downstream insights-ranging from segmentation-specific implications to regional strategic considerations-and to evaluate actions that preserve clinical excellence while improving operational resilience.
A comprehensive view of the transformative technological and clinical shifts that are redefining cerebral angiography practice and procurement imperatives
The cerebral angiography landscape is experiencing transformative shifts driven by digitalization, procedural convergence, and clinician-driven innovation. Image acquisition hardware is increasingly paired with advanced software suites that enable multi-modality fusion, lower radiation exposure, and improved visualization of complex vascular anatomy. Concurrently, the migration from analog to digital workflows is accelerating data portability and clinical analytics, fostering predictive maintenance of equipment and enabling remote support models that extend the useful life of capital assets.
Beyond pure technology, procedural settings are shifting as hybrid operating rooms and integrated catheterization labs support combined diagnostic and interventional workflows. This operational convergence compels stakeholders to prioritize modularity and interoperability when specifying new systems. Moreover, emerging trends such as AI-assisted image interpretation and automated vessel segmentation are starting to influence clinical pathways by augmenting diagnostic confidence and procedure planning. Taken together, these shifts are driving purchasers and clinical leaders to reassess procurement criteria to emphasize software upgradeability, lifecycle cost management, and evidence of impact on clinical outcomes.
An incisive analysis of how twenty twenty five United States tariff adjustments have reshaped supply chain resilience procurement practices and vendor strategies in cerebral angiography
The implementation of escalated tariff measures in the United States during twenty twenty five has layered additional complexity onto the global cerebral angiography supply chain, influencing component sourcing, pricing negotiations, and inventory strategies. Suppliers that rely on cross-border production of high-precision detectors, X-ray generators, and specialist electronics have had to reassess supplier contracts and logistics to mitigate duty-related cost pressures. As a consequence, procurement cycles have often lengthened while stakeholders evaluated alternatives such as nearshoring critical components, increasing local assembly, or renegotiating long-term service agreements to absorb incremental costs.
Clinicians and hospital procurement teams have responded by intensifying dialogue with original equipment manufacturers to secure clearer total cost of ownership commitments and stronger uptime guarantees. Meanwhile, vendors have explored design tweaks to reduce dependence on tariff-exposed imports, and some have optimized configurations to facilitate compliance with domestic content incentives. Importantly, these adaptations have highlighted the need for greater transparency in component provenance, accelerated qualification processes for alternative suppliers, and stronger scenario planning that integrates tariff volatility into capital allocation and clinical implementation timelines.
Segment-specific insights illuminating how equipment type operation mode application and end-user profiles drive differentiated adoption dynamics and procurement criteria in cerebral angiography
Segment-level dynamics reveal differentiated adoption patterns and procurement priorities that align with equipment type, operation mode, application, and end-user settings. Based on Equipment Type, market is studied across Fixed and Mobile, and this distinction maps directly to clinical workflow priorities: fixed systems typically anchor hybrid suites where extensive integration and advanced functionalities are required, while mobile systems enable flexible deployment across procedural areas and support outreach programs or satellite facilities.
Based on Operation Mode, market is studied across Analog and Digital, highlighting a clear migration toward digital platforms that facilitate image post-processing, remote diagnostics, and software-driven enhancements. Based on Application, market is studied across Diagnostic and Interventional, which underscores divergent requirements around frame rate, detector sensitivity, and catheter guidance tools; diagnostic use cases emphasize high-quality vascular mapping while interventional applications prioritize real-time fluoroscopic guidance and device visualization. Based on End User, market is studied across Ambulatory Surgical Centers and Hospitals, with Hospitals further studied across Private Hospitals and Public Hospitals, emphasizing how capital planning, reimbursement pathways, and case mix drive differentiated purchasing criteria. Together, these segmentation lenses reveal where investment in upgradeable software, modular hardware, and clinical training will yield the greatest operational and clinical returns.
A strategic regional analysis that contrasts the distinct regulatory procurement and clinical adoption patterns across the Americas Europe Middle East Africa and Asia Pacific
Regional dynamics are shaping adoption trajectories and strategic priorities across three macro regions that exhibit distinct clinical, regulatory, and procurement characteristics. In the Americas, health systems often prioritize rapid access to advanced interventional capabilities and place a premium on service networks, clinical training programs, and strong evidence of procedural efficacy. This regional orientation supports continued investment in hybrid suites and deep vendor partnerships that offer comprehensive lifecycle services and local technical support.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization, public procurement frameworks, and varying payer models influence adoption speed. Stakeholders in these markets emphasize compliance, cost containment, and scalable solutions that can be deployed across diverse health infrastructures. Asia-Pacific is characterized by rapid capacity expansion, strong demand for mobile and modular solutions, and an increasing focus on localized manufacturing and digital integration. Across regions, vendors and purchasers must align product roadmaps with regulatory expectations, service delivery models, and clinical education needs to achieve durable adoption.
Corporate and competitive intelligence revealing how product modularity software differentiation and service models are redefining vendor positioning in cerebral angiography
Corporate strategies among imaging vendors and service providers are converging on three core priorities: product modularity, software-enabled differentiation, and service-led revenue models. Firms are investing in platforms that support incremental capability upgrades so customers can extend equipment lifecycles without comprehensive hardware replacement. At the same time, companies are bolstering software ecosystems that enable advanced visualization, connectivity with hospital information systems, and subscription-based analytics that provide recurring value beyond the initial sale.
Service and aftermarket support increasingly influence purchasing decisions, with extended warranties, remote diagnostics, and clinically focused training programs becoming differentiators. Strategic partnerships between device manufacturers, software developers, and clinical research organizations are producing stronger evidence packages that support adoption in both diagnostic and interventional contexts. In parallel, companies that demonstrate transparent supply chain practices and show agility in sourcing critical components are gaining preferential consideration from health systems focused on operational continuity and risk mitigation.
Practical and prioritized recommendations for clinical leaders procurement officers and vendors to enhance resilience optimize adoption and unlock clinical and operational value in cerebral angiography
Industry leaders should pursue actionable measures that align clinical excellence with resilient procurement and long-term value realization. First, prioritize procurement frameworks that evaluate software upgrade paths, interoperability standards, and total lifecycle service offerings rather than focusing solely on upfront acquisition cost. This shift will support equipment longevity and reduce disruptive capital churn while enabling progressive adoption of advanced imaging capabilities.
Second, diversify supplier networks and incorporate domestic content considerations into sourcing strategies to buffer against tariff-driven volatility and supply chain interruptions. Third, invest in clinician training and multidisciplinary simulation programs that accelerate proficiency with new imaging features and hybrid procedural workflows, thereby improving throughput and outcomes. Fourth, cultivate evidence generation through real-world data capture and collaborative clinical studies to substantiate clinical benefit and support reimbursement dialogues. Finally, adopt flexible contracting models that include outcome-linked service levels and phased rollouts so organizations can scale capabilities in alignment with evolving clinical demand and budgetary cycles.
A rigorous research methodology detailing primary interviews secondary evidence synthesis and cross validated analytical steps that underpin the study's conclusions and limitations
This analysis synthesizes primary and secondary research with a structured approach designed to produce actionable and verifiable insights. Secondary research encompassed peer-reviewed literature, clinical guidelines, regulatory documents, and manufacturer technical specifications to establish a baseline understanding of technology capabilities and clinical best practices. Primary research consisted of semi-structured interviews with interventional neuroradiologists, cath lab managers, procurement specialists, biomedical engineers, and regulatory experts, enabling triangulation of clinical needs, procurement constraints, and operational realities.
Quantitative and qualitative data streams were reconciled through cross-validation processes that included vendor product comparisons, clinical workflow mapping, and scenario analysis for supply chain disruption. Definitions for segmentation and region were applied consistently to ensure comparability across findings, and limitations were documented where evidence gaps existed. Quality control measures included independent expert review of key conclusions and iterative refinement based on stakeholder feedback to ensure the methodology produced reliable insights aligned with real-world decision making.
A concise conclusion synthesizing how technological progression regulatory pressures and procurement strategy converge to shape durable outcomes in cerebral angiography
The cumulative analysis underscores a cerebral angiography landscape in transition, with technological innovation, digital migration, and supply chain pressures jointly shaping clinical adoption and procurement strategies. Stakeholders that emphasize modularity, software-driven capabilities, and robust service arrangements will be best positioned to navigate regulatory expectations and evolving clinical workflows. At the same time, heightened tariff sensitivity and supply chain complexity require proactive sourcing strategies and closer vendor collaboration to maintain uptime and manage total cost implications.
Ultimately, clinical leaders and procurement teams can derive durable advantage by aligning investment decisions with long-term clinical pathways, prioritizing interoperability and upgradeability, and by fostering evidence generation that demonstrates outcome and workflow improvements. The confluence of procedural innovation and market dynamics creates an environment where deliberate, evidence-led decisions will determine which organizations achieve operational resilience and improved patient care.
Note: PDF & Excel + Online Access - 1 Year
An authoritative introduction framing how technological advances and clinical practice evolution are reshaping cerebral angiography delivery and strategic decision making
Cerebral angiography continues to occupy a pivotal role at the intersection of neurovascular diagnosis and minimally invasive intervention. Advances in imaging hardware, software, and procedural technique have converged to reshape how clinicians visualize cerebrovascular anatomy, assess pathological flow dynamics, and guide high-precision interventions. As the clinical community moves toward tighter integration of real-time imaging, contrast optimization, and dose-minimizing workflows, providers and device stakeholders face new imperatives around interoperability, service continuity, and evidence generation to demonstrate clinical and economic value.
This introduction frames the subsequent analysis by outlining core technological trends, evolving clinical pathways, and systemic pressures that influence procurement and adoption. It emphasizes the growing importance of digital transformation, hybrid procedure suites, and the alignment of clinical protocols with regulatory expectations. By situating cerebral angiography within broader shifts in imaging and vascular care, this section prepares readers to interpret downstream insights-ranging from segmentation-specific implications to regional strategic considerations-and to evaluate actions that preserve clinical excellence while improving operational resilience.
A comprehensive view of the transformative technological and clinical shifts that are redefining cerebral angiography practice and procurement imperatives
The cerebral angiography landscape is experiencing transformative shifts driven by digitalization, procedural convergence, and clinician-driven innovation. Image acquisition hardware is increasingly paired with advanced software suites that enable multi-modality fusion, lower radiation exposure, and improved visualization of complex vascular anatomy. Concurrently, the migration from analog to digital workflows is accelerating data portability and clinical analytics, fostering predictive maintenance of equipment and enabling remote support models that extend the useful life of capital assets.
Beyond pure technology, procedural settings are shifting as hybrid operating rooms and integrated catheterization labs support combined diagnostic and interventional workflows. This operational convergence compels stakeholders to prioritize modularity and interoperability when specifying new systems. Moreover, emerging trends such as AI-assisted image interpretation and automated vessel segmentation are starting to influence clinical pathways by augmenting diagnostic confidence and procedure planning. Taken together, these shifts are driving purchasers and clinical leaders to reassess procurement criteria to emphasize software upgradeability, lifecycle cost management, and evidence of impact on clinical outcomes.
An incisive analysis of how twenty twenty five United States tariff adjustments have reshaped supply chain resilience procurement practices and vendor strategies in cerebral angiography
The implementation of escalated tariff measures in the United States during twenty twenty five has layered additional complexity onto the global cerebral angiography supply chain, influencing component sourcing, pricing negotiations, and inventory strategies. Suppliers that rely on cross-border production of high-precision detectors, X-ray generators, and specialist electronics have had to reassess supplier contracts and logistics to mitigate duty-related cost pressures. As a consequence, procurement cycles have often lengthened while stakeholders evaluated alternatives such as nearshoring critical components, increasing local assembly, or renegotiating long-term service agreements to absorb incremental costs.
Clinicians and hospital procurement teams have responded by intensifying dialogue with original equipment manufacturers to secure clearer total cost of ownership commitments and stronger uptime guarantees. Meanwhile, vendors have explored design tweaks to reduce dependence on tariff-exposed imports, and some have optimized configurations to facilitate compliance with domestic content incentives. Importantly, these adaptations have highlighted the need for greater transparency in component provenance, accelerated qualification processes for alternative suppliers, and stronger scenario planning that integrates tariff volatility into capital allocation and clinical implementation timelines.
Segment-specific insights illuminating how equipment type operation mode application and end-user profiles drive differentiated adoption dynamics and procurement criteria in cerebral angiography
Segment-level dynamics reveal differentiated adoption patterns and procurement priorities that align with equipment type, operation mode, application, and end-user settings. Based on Equipment Type, market is studied across Fixed and Mobile, and this distinction maps directly to clinical workflow priorities: fixed systems typically anchor hybrid suites where extensive integration and advanced functionalities are required, while mobile systems enable flexible deployment across procedural areas and support outreach programs or satellite facilities.
Based on Operation Mode, market is studied across Analog and Digital, highlighting a clear migration toward digital platforms that facilitate image post-processing, remote diagnostics, and software-driven enhancements. Based on Application, market is studied across Diagnostic and Interventional, which underscores divergent requirements around frame rate, detector sensitivity, and catheter guidance tools; diagnostic use cases emphasize high-quality vascular mapping while interventional applications prioritize real-time fluoroscopic guidance and device visualization. Based on End User, market is studied across Ambulatory Surgical Centers and Hospitals, with Hospitals further studied across Private Hospitals and Public Hospitals, emphasizing how capital planning, reimbursement pathways, and case mix drive differentiated purchasing criteria. Together, these segmentation lenses reveal where investment in upgradeable software, modular hardware, and clinical training will yield the greatest operational and clinical returns.
A strategic regional analysis that contrasts the distinct regulatory procurement and clinical adoption patterns across the Americas Europe Middle East Africa and Asia Pacific
Regional dynamics are shaping adoption trajectories and strategic priorities across three macro regions that exhibit distinct clinical, regulatory, and procurement characteristics. In the Americas, health systems often prioritize rapid access to advanced interventional capabilities and place a premium on service networks, clinical training programs, and strong evidence of procedural efficacy. This regional orientation supports continued investment in hybrid suites and deep vendor partnerships that offer comprehensive lifecycle services and local technical support.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization, public procurement frameworks, and varying payer models influence adoption speed. Stakeholders in these markets emphasize compliance, cost containment, and scalable solutions that can be deployed across diverse health infrastructures. Asia-Pacific is characterized by rapid capacity expansion, strong demand for mobile and modular solutions, and an increasing focus on localized manufacturing and digital integration. Across regions, vendors and purchasers must align product roadmaps with regulatory expectations, service delivery models, and clinical education needs to achieve durable adoption.
Corporate and competitive intelligence revealing how product modularity software differentiation and service models are redefining vendor positioning in cerebral angiography
Corporate strategies among imaging vendors and service providers are converging on three core priorities: product modularity, software-enabled differentiation, and service-led revenue models. Firms are investing in platforms that support incremental capability upgrades so customers can extend equipment lifecycles without comprehensive hardware replacement. At the same time, companies are bolstering software ecosystems that enable advanced visualization, connectivity with hospital information systems, and subscription-based analytics that provide recurring value beyond the initial sale.
Service and aftermarket support increasingly influence purchasing decisions, with extended warranties, remote diagnostics, and clinically focused training programs becoming differentiators. Strategic partnerships between device manufacturers, software developers, and clinical research organizations are producing stronger evidence packages that support adoption in both diagnostic and interventional contexts. In parallel, companies that demonstrate transparent supply chain practices and show agility in sourcing critical components are gaining preferential consideration from health systems focused on operational continuity and risk mitigation.
Practical and prioritized recommendations for clinical leaders procurement officers and vendors to enhance resilience optimize adoption and unlock clinical and operational value in cerebral angiography
Industry leaders should pursue actionable measures that align clinical excellence with resilient procurement and long-term value realization. First, prioritize procurement frameworks that evaluate software upgrade paths, interoperability standards, and total lifecycle service offerings rather than focusing solely on upfront acquisition cost. This shift will support equipment longevity and reduce disruptive capital churn while enabling progressive adoption of advanced imaging capabilities.
Second, diversify supplier networks and incorporate domestic content considerations into sourcing strategies to buffer against tariff-driven volatility and supply chain interruptions. Third, invest in clinician training and multidisciplinary simulation programs that accelerate proficiency with new imaging features and hybrid procedural workflows, thereby improving throughput and outcomes. Fourth, cultivate evidence generation through real-world data capture and collaborative clinical studies to substantiate clinical benefit and support reimbursement dialogues. Finally, adopt flexible contracting models that include outcome-linked service levels and phased rollouts so organizations can scale capabilities in alignment with evolving clinical demand and budgetary cycles.
A rigorous research methodology detailing primary interviews secondary evidence synthesis and cross validated analytical steps that underpin the study's conclusions and limitations
This analysis synthesizes primary and secondary research with a structured approach designed to produce actionable and verifiable insights. Secondary research encompassed peer-reviewed literature, clinical guidelines, regulatory documents, and manufacturer technical specifications to establish a baseline understanding of technology capabilities and clinical best practices. Primary research consisted of semi-structured interviews with interventional neuroradiologists, cath lab managers, procurement specialists, biomedical engineers, and regulatory experts, enabling triangulation of clinical needs, procurement constraints, and operational realities.
Quantitative and qualitative data streams were reconciled through cross-validation processes that included vendor product comparisons, clinical workflow mapping, and scenario analysis for supply chain disruption. Definitions for segmentation and region were applied consistently to ensure comparability across findings, and limitations were documented where evidence gaps existed. Quality control measures included independent expert review of key conclusions and iterative refinement based on stakeholder feedback to ensure the methodology produced reliable insights aligned with real-world decision making.
A concise conclusion synthesizing how technological progression regulatory pressures and procurement strategy converge to shape durable outcomes in cerebral angiography
The cumulative analysis underscores a cerebral angiography landscape in transition, with technological innovation, digital migration, and supply chain pressures jointly shaping clinical adoption and procurement strategies. Stakeholders that emphasize modularity, software-driven capabilities, and robust service arrangements will be best positioned to navigate regulatory expectations and evolving clinical workflows. At the same time, heightened tariff sensitivity and supply chain complexity require proactive sourcing strategies and closer vendor collaboration to maintain uptime and manage total cost implications.
Ultimately, clinical leaders and procurement teams can derive durable advantage by aligning investment decisions with long-term clinical pathways, prioritizing interoperability and upgradeability, and by fostering evidence generation that demonstrates outcome and workflow improvements. The confluence of procedural innovation and market dynamics creates an environment where deliberate, evidence-led decisions will determine which organizations achieve operational resilience and improved patient care.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
- 2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
- 3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
- 4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Porter’s Five Forces Analysis
- 4.4. PESTLE Analysis
- 4.5. Market Outlook
- 4.5.1. Near-Term Market Outlook (0–2 Years)
- 4.5.2. Medium-Term Market Outlook (3–5 Years)
- 4.5.3. Long-Term Market Outlook (5–10 Years)
- 4.6. Go-to-Market Strategy
- 5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Cerebral Angiography Market, by Equipment Type
- 8.1. Fixed
- 8.2. Mobile
- 9. Cerebral Angiography Market, by Operation Mode
- 9.1. Analog
- 9.2. Digital
- 10. Cerebral Angiography Market, by Application
- 10.1. Diagnostic
- 10.2. Interventional
- 11. Cerebral Angiography Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Hospitals
- 11.2.1. Private Hospitals
- 11.2.2. Public Hospitals
- 12. Cerebral Angiography Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Cerebral Angiography Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Cerebral Angiography Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. United States Cerebral Angiography Market
- 16. China Cerebral Angiography Market
- 17. Competitive Landscape
- 17.1. Market Concentration Analysis, 2025
- 17.1.1. Concentration Ratio (CR)
- 17.1.2. Herfindahl Hirschman Index (HHI)
- 17.2. Recent Developments & Impact Analysis, 2025
- 17.3. Product Portfolio Analysis, 2025
- 17.4. Benchmarking Analysis, 2025
- 17.5. Abbott Laboratories
- 17.6. AngioDynamics, Inc.
- 17.7. B. Braun Melsungen AG
- 17.8. Bayer AG
- 17.9. Becton, Dickinson and Company
- 17.10. Boston Scientific Corporation
- 17.11. Bracco Imaging S.p.A.
- 17.12. Canon Medical Systems Corporation
- 17.13. Cardinal Health, Inc.
- 17.14. Carestream Health, Inc.
- 17.15. Cook Group Incorporated
- 17.16. GE Healthcare Technologies Inc.
- 17.17. Guerbet S.A.
- 17.18. Hitachi Medical Corporation
- 17.19. Hologic, Inc.
- 17.20. InterMed Medical Limited
- 17.21. Koninklijke Philips N.V.
- 17.22. MEDTRON AG
- 17.23. Medtronic PLC
- 17.24. Merit Medical Systems, Inc.
- 17.25. MicroPort Scientific Corporation
- 17.26. Penumbra, Inc.
- 17.27. Samsung Medison Co., Ltd.
- 17.28. Shimadzu Corporation
- 17.29. Siemens Healthineers AG
- 17.30. St. Stone Medical Devices Private Limited
- 17.31. Stryker Corporation
- 17.32. Terumo Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
